| Project/Area Number |
60440079
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | University of Tokyo |
|---|
Principal Investigator |
YAMASHITA Hidetoshi (1988) Department of Ophthalmology, School of Medicine Univesity of Tokyo, 医学部(病), 講師 (90158163)
堀 貞夫 (1987) 東京大学, 医学部(病), 講師 (20143498)
三島 済一 (1985-1986) 東大, 医学部, 教授 (60009917)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHIRA Akihiko Department of Ophthalmology, School of Medicine University of Tokyo, 医学部(病), 講師 (00114421)
ARAIE Makoto Department of Ophthalmology, School of Medicine University of Tokyo, 医学部(病), 講師 (00092122)
MOCHIZUKI Manabu Department of Ophthalmology, Tokyo University Branch Hospital, 医学部(分院), 助教授 (10010464)
MASUDA Kanjiro Department of Ophthalmology, School of Medicine University of Tokyo, 医学部(病), 教授 (60010188)
山下 英俊 東京大学, 医学部(分院), 講師 (90158163)
谷島 輝雄 東京大学, 医学部(病), 助教授 (50010187)
堀 貞夫 東京大学, 医学部, 講師 (20143498)
|
|---|
| Project Period (FY) |
1985 – 1988
|
| Project Status |
Completed (Fiscal Year 1988)
|
| Budget Amount *help |
¥33,100,000 (Direct Cost: ¥33,100,000)
Fiscal Year 1988: ¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1987: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 1986: ¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1985: ¥27,000,000 (Direct Cost: ¥27,000,000)
|
|---|
| Keywords | Uveitis / corneal transplantation / retinoblastoma / immunotherapy / cyclosporine / シクロスポリン / プロスタグランディンズ / ベーチェット病 / 腎障害 / 全層角煙移植 / 網膜芽細胞腫 / 角膜移植 / 免療抑制剤 / ブドウ膜炎 / 角膜移植後拒絶反応 / モノクローナル抗体 |
|---|
| Research Abstract |
The present research project was aimed at developing new immunotherapies in opthalmology. For the treatment of uveitis, various immunosuppressants were tested in experimental autoimmune uveitis model and it was found that cyclosporine (CsA) had greate capacity to treat uveitis in the animal model. The agent was applied for the treatment of Behcet's disease with refractory uveitis. A total number of 69 patients with Behcet's disease who were resistant to conventional therapy were treated with CsA. The new therapy suppressed ocular attacks of the disease and the visual prognosis was much better than that of conventional hterapy, though CsA had some renal toxicity. CsC was also tested in animal model for its efficay in uveitis and it was found that CsC was effective to suppress uveitis in animals with much less renal toxicity. For the treatment of rejection of corneal transplantation, a new model for drug assay was established using rats. Penetrating keratoplasty was performed in inbred strains of rats having different MHC antigen. Using the model, the effects of CsA was assayed. For the treatment of retinoblastoma, monoclonal antibodies to retinobalstoma was established. Furthermore, effects of prostaglandins were eveluated using retinoblastoma cell line, Y-79 cells. PGD_2 and J_2 were found to have capacities to suppress retinoblastoma cells in vitro as well as in vivo. A monoclonal antibodies to retinoblastoma cell line, m-1131, was found to respond to fresh human retinoblastoma but not to other human tumors.
|
